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SPARC (secreted protein acidic and rich in cysteine) is an extracellular Ca
2þ-binding matricellular glycoprotein associated with the
regulation of cell adhesion and growth. We investigated loss of expression of SPARC gene and promoter methylation in lung cancers
and correlated the data with clinicopathological features. We observed loss of SPARC expression in 12 of 20 (60%) lung cancer cell
lines. Treatment of expression-negative cell lines with a demethylating agent restored expression in all cases. Methylation frequencies
of SPARC gene were 55% in 20 lung cancer cell lines. Primary tumours had methylation at a rate of 69% (119 of 173), while
nonmalignant lung tissues (n¼60) had very low rates (3%). In lung adenocarcinomas, SPARC methylation correlated with a negative
prognosis (P¼0.0021; relative risk 4.65, 95% confidence interval 1.75–12.35, multivariate Cox’s proportional-hazard model).
Immunostaining revealed protein expression in bronchial epithelium (weak intensity) and in juxtatumoral stromal tissues (strong
intensity) accompanied by frequent loss in cancer cells that correlated with the presence of methylation (Po0.001). Our findings are
of biological interest and potentially of clinical importance in human lung cancers.
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The matricellular protein SPARC (secreted protein acidic and rich
in cysteine), also known as osteonectin/BM-40, is a calcium-
binding glycoprotein that shows a high degree of interspecies
sequence conservation and plays an important role in cell–matrix
interactions during tissue remodelling, wound repair, morphogen-
esis, cellular differentiation, cell migration, and angiogenesis
(Sage et al, 1989; Jendraschak and Sage, 1996; Yan and Sage,
1999; Bradshaw and Sage, 2001; Brekken and Sage, 2001). Its role
in tumorigenesis is complex, and expression is often being
downregulated in tumour cells accompanied by upregulation in
juxtatumoral stromal cells. SPARC is highly expressed in
reactive fibroblasts, and expression is deregulated in many types
of human malignant tumours (Porte et al, 1995; Le Bail et al, 1999;
Rempel et al, 1999; Paley et al, 2000). SPARC may promote
vascularisation of tumours, tumour progression, or invasiveness
by modulating the activity of cytokines and stimulating secretion
of tissue remodelling metalloproteases (Lane and Sage, 1994;
Motamed and Sage, 1997; Sage, 1997). Owing to the correlation
between expression and invasion, SPARC was thought to be a
proinvasive protein (Everitt and Sage, 1992a,b; Lane et al, 1994;
Ledda et al, 1997). However, ovarian cancer cells treated
with SPARC showed inhibition of cell proliferation and underwent
apoptosis (Yiu et al, 2001). SPARC potently inhibited angiogenesis
and significantly impaired neuroblastoma tumour growth
in vivo (Chlenski et al, 2002). Implanted Lewis lung carcinoma
cells grew more rapidly in SPARC null mice (Brekken et al, 2003).
Thus, the exact role of SPARC in tumour growth and progression
is unclear.
DNA methylation is a major mechanism associated with the
inactivation of tumour suppressor genes in cancer (Esteller et al,
2001; Jones and Baylin, 2002; Suzuki et al, 2004). It has been
reported that SPARC is silenced through DNA methylation in
pancreatic cancer cells (Sato et al, 2003). SPARC protein by
immunostaining was overexpressed in stromal fibroblasts im-
mediately adjacent to the neoplastic epithelium in pancreatic
cancers, suggesting SPARC expression in juxtatumoral tissues is
regulated through tumour–stromal interactions (Sato et al, 2003).
As exogenous SPARC inhibits the growth of pancreatic cancer cells
in vitro, tumour–stromal interactions of SPARC may act to
facilitate or retard tumour progression (Sato et al, 2003).
In non-small-cell lung cancer (NSCLC), SPARC expression by
immunostaining was also found strongly in stromal fibroblasts,
persistently in chondrocytes of bronchial cartilage, weakly in
bronchial epithelium, but not in alveolar cells nor in tumour cells
(Koukourakis et al, 2003). SPARC, is located at 5q33.1, a region
that demonstrates frequent loss of heterozygosity in idiopathic
pulmonary fibrosis and small-cell lung cancer (SCLC) (Girard et al,
2000; Demopoulos et al, 2002).
In this study, we examined the mRNA expression and
methylation of SPARC in lung cancer cell lines, and examined
the methylation and protein by immunostaining in primary
tumours. We correlated these findings with clinicopathologic
features.
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Cell lines and tumour samples
We studied 12 NSCLC cell lines (NCI-H460, NCI-H1437, NCI-
H1770, NCI-H2087, NCI-H2122, NCI-H2126, HCC15, HCC95,
HCC193, HCC366, HCC515, HCC1171) and eight SCLC cell lines
(NCI-H69, NCI-H146, NCI-H209, NCI-H211, NCI-H524, NCI-
H526, NCI-H1672, NCI-H2171) that were established by us (Phelps
et al, 1996), several of which are deposited in the American Type
Culture Collection (Manassas, VA, USA). Cell cultures were grown
in RPMI-1640 medium (Life Technologies Inc., Rockville, MD,
USA) supplemented with 5% fetal bovine serum and incubated in
5% CO2 at 371C. Cell lines established at the National Cancer
Institute have the prefix NCI, while those established at UT
Southwestern Medical Center have the prefix HCC. Nonmalignant
human bronchial epithelial cells (NHBEC) were cultured as
reported previously (Toyooka et al, 2002), and normal trachea
RNA was obtained from Clontech (Palo Alto, CA, USA).
Surgically resected samples were obtained from patients with
lung cancer who had not received treatment prior to resection at
the Chiba University Hospital, Japan, after obtaining Institutional
Review Board approval and informed consent. Samples were
immediately frozen and stored at  801C until used.
Reverse transcription–polymerase chain reaction
(RT–PCR) assay
An RT–PCR assay was used to examine SPARC mRNA expression.
Total RNA was extracted from the samples with Trizol (Life
Technologies, Rockville, MD, USA) following the manufacturer’s
instructions. RT reaction was performed on 4mg total RNA with
deoxyribonuclease I and the SuperScript II First-Strand Synthesis
using oligo-(dT) primer System (Life Technologies), and aliquots
of the reaction mixture were used for the subsequent PCR
amplification. The forward PCR amplification primer of SPARC
was 50-AAGATCCATGAGAATGAGAAG-30 (Ex8-S), and the re-
verse primer 50-AAAAGCGGGTGGTGCAATG-30 (Ex9-AS) (Acces-
sion number NM_003118; forward, nucleotides 649–669; reverse,
nucleotides 847–865). These sequences are separated by an intron,
and we confirmed that genomic DNA was not amplified with these
primers. Polymerase chain reaction amplification was carried out
for 12min at 951C for initial denaturation, followed by 33 cycles of
941C for 30s, 601C for 30s, and 721C for 45s. The housekeeping
gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was
used as an internal control to confirm the success of the RT
reaction. The primers for GAPDH amplification were as follows:
forward primer, 50-CACTGGCGTCTTCACCACCATG-30; and re-
verse primer, 50-GCTTCACCACCTTCTTGATGTCA-30. Polymerase
chain reaction amplification was carried out for 12min at 951C for
initial denaturation, followed by 25 cycles of 941C for 30s, 651C for
45s, and 721C for 30s. These primer sequences were identical to
the human target genes as confirmed by a BLAST search.
Polymerase chain reaction products were analysed on 2% agarose
gels. Nonmalignant human bronchial and normal trachea were
used as normal controls for RT–PCR.
5-Aza-20-deoxycytidine (5-Aza-CdR) treatment
In all, 11 tumour cell lines with SPARC hypermethylation and
absent gene expression were incubated in culture medium with
4mM 5-Aza-CdR for 6 days, with medium changes on days 1, 3, and
5. The cells were harvested and RNA was extracted at day 6.
DNA extraction and methylation-specific PCR (MSP)
Genomic DNA was obtained from cell lines, cultured nonmalig-
nant cells, primary tumours, and nonmalignant tissues by
digestion with proteinase K (Life Technologies), followed by
phenol/chloroform (1:1) extraction (Herrmann and Frischauf,
1987). DNA methylation patterns in the CpG island of SPARC were
determined by the method of MSP as reported by Herman et al
(1996). Primer sequences of SPARC for unmethyalted reaction
were 50-TTTTTTAGATTGTTTGGAGAGTG-30 (sense) and 50-AAC-
TAACAACATAAACAAAAATATC-30 (antisense), and for the
methylated reaction, 50-GAGAGCGCGTTTTGTTTGTC-30 (sense)
and 50-AACGACGTAAACGAAAATATCG-30 (antisense) (Sato et al,
2003). Briefly, 1mg of genomic DNA was denatured by NaOH and
modified by bisulfite. The modified DNA was purified using
Wizard DNA purification kit (Promega, Madison, WI, USA),
treated with NaOH to desulphonate, precipitated with ethanol, and
resuspended in water. Polymerase chain reaction amplification was
carried out for 12min at 951C for initial denaturation, followed by
38 cycles of 941C for 20s, 621C for 20s, and 721C for 30s. DNA
from peripheral blood lymphocytes (n¼14) from healthy non-
smoking subjects was used as negative controls for methylation-
specific assays. DNA from lymphocytes of a healthy volunteer
treated with Sss1 methyltransferase (New England BioLabs,
Beverly, MA, USA) and then subjected to bisulfite treatment was
used as a positive control for methylated alleles. Water blanks were
included with each assay. Polymerase chain reaction products were
visualised on 2% agarose gels stained with ethidium bromide.
Immunostaining
SPARC was detected on paraffin-embedded tissue sections by the
avidin–biotin peroxidase complex method using a mouse mono-
clonal antibody generated against the N-terminal region of SPARC
(AON-5031; Hematologic Technologies Inc., Essex Junction, VT,
USA). After immunostaining, the sections were counterstained
with haematoxylin, dehydrated, and mounted.
Immunostaining was graded by two independent observers
unaware of clinical or laboratory findings. Staining was categorised
from 0 to 4þ based on the percentage of cells stained. Score 0 was
assigned if less than 5% of cells were positive. A weak staining
(þ1) was assigned if 6–25% of cells were positive, a moderate
staining (2þ) was assigned if 26–50% of cells were positive, high
sore (3þ) was assigned if 51–75% of cells were positive, and a
very high score (þ4) was assigned if more than 75% of cells
stained positive. The degree of staining intensity was also noted.
Statistical analysis
Statistical differences between groups were examined using
Fisher’s exact test, w
2 test, and Mann–Whitney test. Survival was
calculated from the date of initial diagnosis until death or the date
of the last follow-up (censored). Survival was analysed according
to the Kaplan–Meier method, and differences in their distribution
were evaluated by means of the log-rank test. A multivariate Cox’s
proportional-hazard model was developed to evaluate the covari-
ates’ joint effects. All P’s are two-sided, and P of less than 0.05 was
defined as being statistically significant.
RESULTS
Aberrant methylation and expression of SPARC in cell
lines
Expression of SPARC was examined by RT–PCR, and representa-
tive examples are shown in Figure 1A. SPARC expression was
present in NHBEC and normal trachea. However, loss of SPARC
expression was observed in 10 of 12 (83%) NSCLC cell lines, and
two of eight (25%) SCLC cell lines (Table 1 and Figure 1B).
Aberrant methylation was absent in DNA from peripheral blood
lymphocytes from healthy nonsmoking volunteers (n¼14) and
NHBEC. Aberrant methylation was found in nine of 12 (75%)
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of expression and lack of methylation of SPARC were found in
NSCLC cell line NCI-H2126, suggesting an alterative method of
gene silencing in this cell line. The concordance between loss of
gene expression and aberrant methylation of SPARC was 92% in
NSCLC cell lines, and 100% in SCLC cell lines (overall concordance
95%).
5-Aza-20-deoxycytidine treatment
Nine NSCLC cell lines (NCI-H460, NCI-H1437, NCI-H2087, NCI-
H2122, HCC15, HCC95, HCC366, HCC515, HCC1171) and two
SCLC cell lines (NCI-H146, NCI-H211) that showed loss of
expression and methylation of SPARC were cultured with the
demethylating agent 5-Aza-CdR. SPARC expression was restored
after treatment in all 11 methylated cell lines tested (Figure 1C).
Aberrant methylation of SPARC in primary tumours
Results of aberrant methylation of SPARC in primary tumours and
nonmalignant tissues are detailed in Table 1 and Figure 1D. SPARC
methylation was a tumour-specific event in lung cancers
(P¼0.0001) when compared with corresponding adjacent non-
malignant tissues.
Of 173 lung cancers, 119 (69%) were found to be methylated.
There was a significant relationship between the major histologic
types of lung cancer, NSCLC (115 of 161, 71%) and SCLC (four of
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Figure 1 (A) Representative examples of RT–PCR for SPARC in lung
cancer cell lines, NHBEC, and normal trachea. GAPDH was used as a
control for the RNA integrity and RT reactions. NC¼negative control. (B)
Representative examples of MSP assay in cell lines. Polymerase chain
reaction products were visualised on 2% agarose gels stained with ethidium
bromide. M¼methylated band; U¼unmethylated band. (C) Representa-
tive examples of RT–PCR for SPARC mRNA in lung cancer cell lines before
( ) and after (þ) treatment with 5-Aza-CdR. (D) Representative
examples of MSP assay in primary tumours and nonmalignant tissues. All
PCR products were visualised on 2% agarose gels stained with ethidium
bromide. M¼methylated band; U¼unmethylated band; T¼lung cancer
tissues; N¼nonmalignant lung tissue; PC¼positive control.
Table 1 SPARC methylation in lung cancers
Samples Total no. No. methylated (%)
Tumours 193
Cell lines
NSCLC cell lines 12 9 (75)
SCLC cell lines 8 2 (25)
Primary NSCLC
Adenocarcinoma 84 57 (68)
Squamous cell carcinoma 61 52 (85)
Large-cell carcinoma 11 6 (55)
Others 5 0 (0)
Primary SCLC 12 4 (33)
Nonmalignant 74
Lung tissues and NHBEC 60 2 (3)
Peripheral blood mononuclear cells
a 14 0 (0)
NSCLC¼non-small-cell lung cancer; SCLC¼small-cell lung cancer;
NHBEC¼nonmalignant human bronchial epithelial cells.
aFrom healthy nonsmoking
volunteers.
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Stage I, II (n = 34)
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B
Figure 2 Overall survival for 84 lung adenocarcinoma patients with early
stages (n¼34) or advanced stages (n¼50) (A), or with (n¼57) or
without (n¼27) the methylation of SPARC (B). Probability of survival
curves was calculated using the Kaplan–Meier product-limit method and
compared via the log-rank test between groups.
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there was no significant association with gender, age, smoking
history, or tumour stage. However, the frequency of methylation
was significantly higher in squamous cell carcinomas (52 of 61,
85%) compared to adenocarcinomas (57 of 84, 68%) (P¼0.01).
Overall survival of adenocarcinomas was poorer in patients with
SPARC methylation than in those without methylation (P¼0.008;
log-rank test; Figure 2) and for patients with advanced stages
(P¼0.0005). In a multivariate Cox’s proportional-hazard model,
promoter methylation of SPARC was an independent adverse
prognostic factor (P¼0.0021; relative risk (RR) 4.65, 95%
confidence interval (CI) 1.75–12.35) next to stage (P¼0.0003;
RR 4.44, 95% CI 1.98–9.90) in adenocarcinoma cases (Table 2).
Immunostaining of SPARC protein in lung cancer
The expression of SPARC protein was examined in 162 primary
lung cancers by immunostaining (Figure 3). In nonmalignant lung
tissues, 73 of 128 cases (57%), negative (0) to weak (1þ) SPARC
expression was found in bronchial epithelial cell, while moderate
(2þ) to very strong (4þ) expression was found in 55 cases.
Alveolar cells were negative except for one case, which showed
weak expression. Stromal fibroblasts distant from tumours showed
negative to weak expression. Inflammatory cells including
lymphocytes were negative expression, while chondrocytes of
bronchial cartilage were moderate (2þ) to strong (4þ) SPARC
expression. In 132 of 162 cases, negative (0) to weak (1þ) SPARC
expression was found in the cancer cells, while moderate (2þ)t o
strong (4þ) SPARC expression was found in 30 cases. Moderate
Table 2 Univariate and multivariate statistics of the prognostic value of
gender, age, smoking, stage, and methylation status of SPARC for survival in
lung adenocarcinomas
Univariate
Multivariate
Number P-value Risk ratio 95% CI P-value
Gender
Female 40 0.76 0.71 0.30–1.65 0.42
Male 44
Age (years)
o64
a 42 0.58 1.73 0.87–3.42 0.12
464 42
Smoking
Nonsmoker 39 0.43 1.52 0.65–3.57 0.34
Smoker 45
Stage
I, II 34 0.0005 4.44 1.98–9.90 0.0003
III, IV 50
SPARC methylation
  27 0.008 4.65 1.75–12.35 0.0021
+5 7
Results of univariate analyses using the log-rank test and multivariate analyses using
Cox’s proportional-hazard model of prognostic factors for overall survival. Stage and
SPARC methylation are significantly associated with poor survival. CI¼confidence
interval; SPARC¼secreted protein acidic and rich in cysteine.
aDivided by median age
of adenocarcinoma cases.
Figure 3 Immunostaining for SPARC in normal and malignant lung tissues. (A) Weak to moderate expression (1–2þ) of SPARC by bronchial
epithelium. Most of the staining is present in the apical surface of ciliated surface cells. (B) Bronchioli showed negative (0) expression. (C) Strong (3þ)
reactivity for SPARC in adenocarcinoma cells that lacked DNA methylation of SPARC gene, while alveolar cells and stromal cells are negative. (D) Negative
immunostaining for SPARC in an adenocarcinoma demonstrating DNA methylation, while the adjacent stromal cells demonstrate very strong (4þ)
reactivity for SPARC;  200 magnification.
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162 cases in stromal cells near to or surrounding cancer cells.
Thus, the predominant immunostaining pattern was negative in
tumour cells while being positive in corresponding juxtatumoural
stromal cells (125 of 162, 77%). However, there was no correlation
of immunostaining pattern between tumour cells and stromal cells
(Table 3A). Immunostaining pattern of neither tumour cells nor
stromal cells correlated with patients’ survival (data not shown). Of
162 cases, 105 showed loss (0) or weak (1þ) expression of SPARC
protein and methylation of SPARC gene, and 19 cases showed
moderate (2þ) to very strong (4þ) expression without methyla-
tion (Table 3B). Thus, the concordance between methylation and
loss of gene expression in tumour cells was 77% (Po0.0001).
There was no correlation between tumour methylation and stromal
cell immunostaining.
DISCUSSION
Sato et al demonstrated downregulation of SPARC mRNA in
pancreatic cancer cells through DNA methylation (Sato et al,
2003). In our study, we observed that decreased SPARC expression
in lung cancer cell lines is associated with DNA methylation of the
gene promoter, and it is re-expressed by treatment with the
demethylating agent 5-Aza-CdR in lung cancer cell lines. Although
there are other possible mechanisms for downregulation of SPARC
expression, the excellent concordance between mRNA expression
by RT–PCR or protein expression by immunostaining and DNA
methylation of SPARC indicates that the gene is downregulated
mainly through DNA methylation in lung cancer.
As with other tumours, SPARC is downregulated in lung cancer
cells while being upregulated in juxtatumoural stromal cells.
Upregulation was unusual in stromal cells distant from the
tumour. These findings result in a complex pattern of simulta-
neous selective downregulation in a specific cell type (tumour
cells) accompanied by selective upregulation in adjacent stromal
cells. A similar pattern has been previously described in ovarian,
pancreatic, and lung cancers (Brown et al, 1999; Koukourakis et al,
Table 3 (A) SPARC immunostaining in tumour and stromal cell
(n¼162) and (B) methylation and immunostaining of SPARC in tumours
(n¼162)
Tumour cell Stromal cell No. (%) P-value
a
(A)
Positive Positive
b 29 (18) 40.9
Positive Negative
c 1 (1)
Negative Positive 125 (77)
Negative Negative 7 (4)
Tumour methylation Tumour immunostaining No. (%) P-value
(B)
Methylated Positive 11 (7) o0.0001
Methylated Negative 105 (65)
Unmethylated Positive 19 (12)
Unmethylated Negative 27 (17)
Tumour methylation Stromal immunostaining No. (%) P-value
Methylated Positive 110 (68) 40.9
Methylated Negative 6 (4)
Unmethylated Positive 44 (27)
Unmethylated Negative 2 (1)
SPARC¼secreted protein acidic and rich in cysteine.
aFisher’s exact probability.
bPositive reveals moderate (2+) to very strong (4+) immunostaining.
cNegative
reveals negative (0) to weak (1+) immunostaining.
Table 4 (A) Expression of SPARC in various tumours and (B) functional analyses of SPARC for tumorigenesis in tumour cell lines
Tumour type
Type of
material
Method for detecting
expression
Frequency or level of
expression compared to
nonmalignant tissues Reference
(A)
Lung cancer Tissue RT–PCR 18% Schneider et al (2004)
Lung cancer Tissue Immunostaining 5% Koukourakis et al (2003)
Barrett’s oesophagus Tissue RT–PCR High (P¼0.004) Brabender et al (2003)
Pancreatic adenocarcinoma Cell lines/tissue RT–PCR/immunostaining 12%/32% Sato et al (2003)
Oesopahgeal carcinoma Tissue Immunostaining 100% Yamashita et al (2003)
Bladder cancer Tissue RT–PCR High (Po0.0001)
a Yamanaka et al (2001)
Ovarian cancer Tissue Immunostaining 14% Paley et al (2000)
Metastatic prostate cancer Tissue Immunostaining High (most)
b Thomas et al (2000)
Invasive meningioma Tissue Immunostaining 100% Rempel et al (1999)
Malignant melanoma Tissue Immunostaining 63.8% Massi et al (1999)
Hepatocellular carcinoma Tissue Immunostaining 91%
c Le Bail et al (1999)
Tumour type Expression
d Effect for tumorigenesis Reference
(B)
Pancreatic adenocarcinoma High Growth suppression Sato et al (2003)
Prostate cancer High Promotion of cell migration
to bone
De et al (2003)
Lewis lung adenocarcinoma Null More rapid growth Brekken et al (2003)
Neuroblastoma High Impairing of tumour growth Chlenski et al (2002)
Breast cancer High with c-Jun Increase of motility and
invasion
Briggs et al (2002)
Glioma High Promotion of invasion Schultz et al (2002)
Ovarian cancer High Inhibition of the proliferation Yiu et al (2001)
SPARC¼secreted protein acidic and rich in cysteine; RT–PCR¼reverse transcription–polymerase chain reaction.
aStage T2 or greater invasive tumours compared to stages T1
or less tumours.
bHigh levels of SPARC protein were observed in most of the metastatic foci.
cHigh in the stromal myofibroblasts of the tumour tissues.
dForced expression by
endogenous or exogenous SPARC.
SPARC methylation in lung cancer
M Suzuki et al
946
British Journal of Cancer (2005) 92(5), 942–948 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s2003; Sato et al, 2003). Our findings demonstrate that the
mechanism of downregulation of SPARC in lung cancer cells is
due to methylation. The dual up- and downregulation of SPARC in
tumours makes interpretation difficult, while its role in tumor-
igenesis remains controversial. SPARC may function similar to
TGFb, where signaling is downregulated in cancer cells early in
tumorigenesis, but is overexpressed at later stages, thus acting
either as tumour suppressor or oncogene, depending on the
tumour stage (Wakefield and Roberts, 2002). Our data indicate
that tumour–host interactions between lung cancer cells and
stromal cells through SPARC protein play an important role in the
pathogenesis of lung cancers.
Our data demonstrated that methylation of SPARC gene in
tumour cells had poorer prognosis in lung adenocarcinomas,
whereas reactivity of stromal fibroblasts had been reported to
correlate worse prognosis in NSCLC (Koukourakis et al, 2003). The
expression of SPARC in cancer tissues or functional analyses of
SPARC gene in tumour cell lines have been widely studied
(Table 4). Expression, as analysed by RT–PCR or immunostaining,
was downregulated in lung, pancreatic, and ovarian cancers,
whereas it was upregulated in oesophageal, bladder, metastatic
prostate, hepatocellular cancers, and invasive meningiomas and
malignant melanomas, and some of those findings were supported
by functional analyses. The expression of SPARC by both normal
and tumour cells is highly dependent on tumour type and culture
conditions. Expression of SPARC in cancer tissues correlated with
poor prognosis in malignant melanoma, bladder, and oesophageal
carcinoma as also reported by others, although some of these
reports was analysed by RT–PCR using whole specimens (Massi
et al, 1999; Yamanaka et al, 2001; Yamashita et al, 2003). Aberrant
expression of SPARC in primary tumours may result in negative
prognosis.
In conclusion, SPARC was downregulated in cancer cells
through DNA methylation and overexpressed in its stromal cells
of lung cancer, and DNA methylation correlated with prognosis in
adenocarcinomas. DNA methylation of SPARC may play a role in
the pathogenesis of lung cancers.
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